BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said on Monday that Shanghai Fosun High Technology, a subsidiary of Fosun International (0656.HK), has pledged 198 million shares of the Shanghai-listed…
Shunned by investors, Henlius hangs up on its Hong Kong listing
The Fosun-backed drugmaker’s privatization comes as its stock price has wilted over 60% since its IPO five years ago and it failed to use the listing to raise additional funds…
FAST NEWS: Fosun Pharma hits pause button on share buyback program
The Latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced Monday it hasn't yet implemented a share buyback since announcing a plan on March 27 to buy back its A shares…
Fosun International on cusp of new ‘asset-light’ era with latest sale
The conglomerate is selling its stake in multinational insurer Ageas, extending a slimming exercise touched off by a liquidity crisis in 2022 Key Takeaways: Fosun International’s total debt-to-capitalization ratio stood…
FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
FAST NEWS: Henlius swings to the black on strong sales growth
The latest: Shanghai Henlius Biotech Inc. (2696.HK) on Wednesday reported a net profit of 408 million yuan ($56.2 million) in the first three quarters of this year, reversing a loss of…
Debt pressures cast cloud over Fosun Pharma results
The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
